title: Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study.
abstract: OBJECTIVE
  This follow-up study was performed to assess the long-term effects of paclitaxel-eluting stents (PES) compared with bare-metal stents (BMS) in patients who had undergone a percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
  
  
  RESULTS
  The PASSION trial randomly assigned 619 patients with STEMI to receive either a PES or BMS. The composite endpoint for the follow-up study was the occurrence of the combination of cardiac death, recurrent myocardial infarction, target lesion revascularisation (TLR) or stent thrombosis at two years. A trend towards a lower rate of the composite endpoint was observed in the PES compared to the BMS group (hazard ratio [HR] 0.70; 95% C.I. 0.45-1.09). This was driven by a reduced TLR in favour of PES (HR 0.60; 95% C.I. 0.34-1.09). Angiographically proven stent thrombosis at two years did not differ significantly between groups (2.1% in the PES group versus 1.4%; HR 1.48; 95% C.I. 0.42-5.23).
  
  
  CONCLUSIONS
  PES implantation for STEMI did not significantly improve clinical outcome at two years after the index event, although there was a trend towards a lower rate of target-lesion revascularisation. The rate of stent thrombosis did not differ significantly between groups.
authors.affiliation: Department of Interventional Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
authors.forename: Maurits T
authors.initials: MT
authors.lastname: Dirksen
authors.forename: Maarten A
authors.initials: MA
authors.lastname: Vink
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Suttorp
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Mark S
authors.initials: MS
authors.lastname: Patterson
authors.forename: Ton
authors.initials: T
authors.lastname: Slagboom
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Kiemeneij
authors.forename: Gerrit J
authors.initials: GJ
authors.lastname: Laarman
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000401:mortality; D003328:Coronary Thrombosis / Q000401:mortality; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000706:statistics & numerical data; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D008670:Metals; D017239:Paclitaxel